SEC Company Response from Bicara Therapeutics (BCAX) — Nov 24, 2025
Bicara Therapeutics Inc.
Date: Nov. 24, 2025 · CIK: 0002023658 · Accession: 0001193125-25-293647
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290707
Letter
Re:
VIA EDGAR November 24, 2025 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Bicara Therapeutics Inc. Acceleration Request for Registration Statement on Form S-3 Filed October 3, 2025 File No. 333-290707 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Bicara Therapeutics Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to November 26, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Kathryn W. Clerici at (617) 570-1363. If you have any questions regarding this request, please contact Kathryn W. Clerici of Goodwin Procter LLP at (617) 570-1363.
Sincerely,
Bicara Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR November 24, 2025 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Bicara Therapeutics Inc. Acceleration Request for Registration Statement on Form S-3 Filed October 3, 2025 File No. 333-290707 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Bicara Therapeutics Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to November 26, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Kathryn W. Clerici at (617) 570-1363. If you have any questions regarding this request, please contact Kathryn W. Clerici of Goodwin Procter LLP at (617) 570-1363. Sincerely, Bicara Therapeutics Inc. /s/ Claire Mazumdar Claire Mazumdar, Ph.D. Chief Executive Officer cc: Ivan Hyep, Bicara Therapeutics Inc. Lara Meisner, Esq., Bicara Therapeutics Inc. Kingsley L. Taft, Esq. Goodwin Procter LLP Gabriela Morales-Rivera, Esq. Goodwin Procter LLP Kathryn W. Clerici, Esq., Goodwin Procter LLP